Naglaa Zayed

Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial

Imam Waked, Gamal Shiha, Roula Qaqish et al. · ˜The œLancet. Gastroenterology & hepatology · 2016 · 74 citations

Medicine, Infectious Diseases, Pharmacotherapy +16

Association of IL28B SNP With Progression of Egyptian HCV Genotype 4 Patients to End Stage Liver Disease

Mostafa K. El Awady, Lotiaf Mostafa, Ashraf A. Tabll et al. · Hepatitis Monthly · 2012 · 57 citations · Full text

Medicine, Immunology, Molecular Genetics +17

Single nucleotide polymorphism at exon 7 splice acceptor site of OAS1 gene determines response of hepatitis C virus patients to interferon therapy

Mostafa K. El Awady, Mohamed A. Anany, Gamal Esmat et al. · Journal of Gastroenterology and Hepatology · 2010 · 52 citations · Full text

Life Sciences, Genetics, Molecular Genetics +17

Circulatory miRNA-484, 524, 615 and 628 expression profiling in HCV mediated HCC among Egyptian patients; implications for diagnosis and staging of hepatic cirrhosis and fibrosis

Shohda A. El‐Maraghy, Ola Adel, Naglaa Zayed et al. · Journal of Advanced Research · 2019 · 46 citations · Full text

Medicine, Molecular Biology, Molecular Medicine +17

Non-Invasive Prediction of Hepatic Fibrosis in Patients With Chronic HCV Based on the Routine Pre-Treatment Workup

Marwa Khairy, M.D. HEBA N.A.H. ABDEL MENAEM ABEER A. ABDEL-RAHMAN, Maissa El Raziky et al. · Hepatitis Monthly · 2012 · 42 citations · Full text

Medicine, Internal Medicine, Pathology +17